Objectives: Using registry data to compare fungaemia caused by uncommon yeast species (UYS; i.e. other than Candida albicans, Candida glabrata, Candida parapsilosis, Candida tropicalis and Candida krusei) and C. albicans-related fungaemia can reveal specific predisposing factors of UYS with potential impact on treatment strategies.
Introduction
Apart from the four main non-albicans species, namely Candida glabrata, Candida tropicalis, Candida parapsilosis and Candida krusei, many uncommon yeast species (UYS) with varying susceptibility to commonly used antifungal drugs are increasingly reported as a new threat to immunocompromised patients. 1 This trend could be explained by better tools for identification of UYS and increased numbers of patients at risk potentially exposed to new opportunistic species. However, the increased reporting of UYS is mainly ascribed to the wider use of antifungal drugs effective against the most common Candida species. Several reviews have underlined the occurrence of uncommon Candida species breakthrough infections with high crude mortality. [1] [2] [3] Therefore, understanding the epidemiological trends of UYS infections has important implications for clinical management in the present era of generalization of prophylactic and/or empirical antifungal treatments. 4 Analysis of epidemiological trends usually relies on broad surveillance studies with limited clinical documentation, or on case V C The Author 2017. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please email: journals.permissions@oup.com.
reports focused on a single institution, resulting in differences between studies in which UYS are often only collaterally considered. 5 The main sources are collections of case reports, which uncover novelties or emergence, but have per se limited epidemiological value. Other sources are studies focusing either on specific UYS [6] [7] [8] [9] [10] [11] [12] [13] [14] and/or on a specific population, mainly cancer patients, [1] [2] [3] which prevents identification of species-specific risk factors.
To overcome these limitations, we launched in 2002 a large prospective hospital-based surveillance programme to study patients developing yeast fungaemia via collection of related microbiological, clinical and therapeutic items, and follow-up. 15 This surveillance led to a comprehensive collection of cases of fungaemia due to common and uncommon yeast species.
In the present study, our objective was to analyse clinical variables associated with UYS infections in comparison with those due to the main species, Candida albicans, used here as a reference, to identify species-specific features that could guide diagnosis and management of UYS-related fungaemia as already proposed. 16 We did not consider grouping all the common species together and using this as a reference because the established inter-species differences in terms of predisposing risk factors and outcome could have blurred the picture for UYS. 4, 15, 17 The advantage of choosing C. albicans, the main species, as a comparator is to allow future comparisons using prospective hospital-based surveillance programmes or similar registries. 16 
Materials and methods

Population studied
The active YEASTS surveillance programme was launched by the French National Reference Centre for Invasive Mycoses & Antifungals (NRCMA) in 2002 with the participation of 27 short-stay university or cancer hospitals in the Paris area. All patients having a blood culture positive for a yeast were enrolled. Demographics, underlying conditions, care in ICU, initial antifungal treatment and outcome up to day 30 were recorded on a standardized questionnaire through a secure website.
The date of fungaemia was that of blood sampling. An incident case was the first positive blood culture. Recurrences included isolation of the same species at least 10 days later or of a new species with no time limit. Surgery or antifungal drug prescription was taken into account within 30 days prior to fungaemia.
Isolate characterization and phylogeny
All isolates were sent to the NRCMA and all species other than C. albicans, C. glabrata, C. tropicalis, C. parapsilosis, C. krusei (syn. Pichia kudriavzevii), and Cryptococcus spp. were considered as UYS. Purity was checked on chromogenic medium. Identification was performed using carbon assimilation profiles (ID32C, bioMérieux, Marcy-l' Etoile, France) before July 2014, and MALDI-TOF from July 2014 onwards. To differentiate Candida dubliniensis and C. albicans, duplex PCR was performed. 18 For all UYS except Saccharomyces cerevisiae and Candida kefyr (synonym Kluyveromyces marxianus), species identification was confirmed by sequence analysis. ITS1-5.8S-ITS2 and D1D2 regions were sequenced by using V9D/LS266 and NL1/NL4 primer sets. For each species, ITS region sequences were trimmed with sequences of primers ITS1 (5 0 -TCCGTAGGTGAACCTGCGG-3 0 ) and ITS4 (5 0 -GCATATCAATAAGCGGAGGA-3 0 ) and the 98% similarity threshold was used to confirm species. 19 In addition, the actin gene (for Candida lusitaniae) 20 and the IGS1 region (for Trichosporon spp.) 21 were sequenced.
To increase sample size, and thus the power of the statistical analysis, we grouped species according to similarity in the ITS sequences keeping in mind taxonomic relevance. Multiple alignments of trimmed sequences were performed using ClustalW (GeneiousV R v. 6.1.8, Biomatters, New Zealand). A neighbour joining tree was constructed with ITS sequences of reference strains, using Geneious and CLC Main Workbench v. 7.6.4 software (Qiagen, Germany). The percentage similarity used for grouping varied from 95.9% to 83.4% (Figure 1 ). The lowest homologies were for the sequences of the INCONSPICUA group (83.4% similarity) and Trichosporon spp. (between 83.8% and 99.4% similarity). For the latter, we decided to keep them as Trichosporon spp. despite recent taxonomic modifications. 22 UYS for which grouping with common non-albicans species would have been more meaningful were not considered here. Thus, Candida nivariensis (n " 1), Candida orthopsilosis (n " 19) or Candida metapsilosis (n " 9) were not further analysed.
All isolates were tested for in vitro susceptibility to five antifungal drugs according to a slight modification of the EUCAST procedure. 23 Caspofungin MICs were determined from the onset of the YEASTS programme as the stable median (range) MIC for the quality-control strain ATCC 6258 [0.12 mg/L (0.06-0.25)] over time. Given the absence of consensus breakpoints for caspofungin and for fluconazole on UYS, MICs were only used for phenotypic characterization. UYS were arbitrarily classified as caspofungin less-susceptible (caspofungin-LS) species if the MIC that inhibited 50% of the isolates (MIC 50 ) was .0.25 mg/L, 24 and as fluconazole less-susceptible (fluconazole-LS) species if the MIC 50 was .4 mg/L as already reported. 25 
Statistical analysis
Analyses were performed on yeasts from single episodes of fungaemia, with one isolate corresponding to one patient. To avoid autocorrelation, recurrences with the same species, or with C. albicans after a UYS episode, were excluded. Risk factors for UYS fungaemia were studied by univariate and multivariate analysis (logistic regression) using C. albicans as reference (and taking into account only variables known at the time of sampling, i.e. treatment and outcome were omitted). For the analysis of risk factor for death, a categorical variable was created that included all UYS involved in more than 20 cases with C. albicans as reference. Univariate analysis was based on v 2 or Fisher's exact test when needed for discrete variables. For the multivariate analysis, baseline non-collinear covariates with a P value ,0.25 in the univariate analysis representing pre-existing conditions before fungaemia or risk factor for death were first included in a full model. They were removed one by one until all of the covariates remaining in the reduced model had a P value ,0.05. Survivals were determined by the Kaplan-Meier method and compared by the log-rank test. Data were analysed using StataV R software (v. 12.1; College Station, TX).
Ethics
The research described herein was carried out in compliance with French law and the Declaration of Helsinki (as adopted in 2000), and was approved by the Institut Pasteur Institutional Review Board #1 (#2009-34/IRB). Approval of the Commission Nationale de l'Informatique et des Libertés was obtained, ensuring that patient data were kept anonymous according to French regulations.
Results
Between 1 October 2002 and 31 December 2014, we collected 4247 isolates (Cryptococcus spp. excluded) of which 403 (9.5%) were UYS as defined above. There was neither a seasonal trend (data not shown) nor any trend towards an increase in the proportion of annual UYS (P " 0.0674) over time (Table S1 available as Supplementary data at JAC Online). In order to be able to determine the effect on each UYS, 48 isolates from mixed episodes involving mainly uncommon ascomycete species with common Candida Uncommon yeast species-related fungaemia JAC species were excluded from the database. To avoid autocorrelation, 17 isolates from recurrent episodes with the same UYS were also excluded ( Figure S1 , Table S2 ). The same restrictions were applied to C. albicans isolates. While mixing the UYS and C. albicans databases, we excluded three additional C. albicans isolates that were recovered from recurrent episodes corresponding to incidents of infection involving UYS to maximize UYS data whilst avoiding autocorrelation due to the same patients experiencing infection by both UYS and C. albicans. The final dataset thus included single episodes of infection with 338 UYS isolates and 1998 C. albicans ( Figure S1 ).
Overall, UYS included 35 different species (27 ascomycetes; 8 basidiomycetes; Table 1 ). Among the 11 caspofungin-LS species, 8 were basidiomycetes. Among the 15 fluconazole-LS species, 2 were basidiomycetes. Only 4 species were both caspofungin-LS and fluconazole-LS (Magnusiomyces capitatus, Saprochaete clavata, Trichosporon dermatis and Rhodotorula mucilaginosa).
The demographic and clinical characteristics of patients with C. albicans infections were successively compared with those with all UYS, caspofungin-LS and fluconazole-LS (Tables 2 and 3 ).
Haematological malignancies, intravenous drug addiction, preexposure to antifungal drugs and solid organ transplantation (SOT) were independently associated with infection with UYS as a whole rather than with C. albicans, whereas older age (.80 years) or surgery within 30 days were associated with C. albicans compared with UYS infection. For the caspofungin-LS species, haematological malignancies, pre-exposure to caspofungin and younger age were associated with infection by caspofungin-LS species compared to C. albicans. Haematological malignancies, SOT, intravenous drug addiction and pre-exposure to antifungal drugs (and not only fluconazole) were associated with infections with fluconazole-LS species rather than C. albicans, whereas surgery within 30 days was associated with C. albicans infections.
We then compared C. albicans infections with those due to specific UYS, as single species or grouped as defined above (Table S3 ). In contrast to the above analysis where haematological malignancy was associated with infection with UYS as a whole, here it was an independent risk factor only for infections with isolates of Trichosporon spp. and of the KEFYR and GEOTRICHUM groups. Pre-exposure to caspofungin was Uncommon yeast species-related fungaemia JAC associated with infections with Trichosporon spp. isolates and isolates of the GUILLIERMONDII and GEOTRICHUM groups. Intravenous drug addiction, SOT, recent surgery and absence of malignancy were associated with infections with isolates belonging to the GUILLIERMONDII group, whereas hospitalization in ICU was protective. HIV infection was a risk factor for C. dubliniensis infections. Finally, acute leukaemia and preexposure to fluconazole were associated with isolates of the INCONSPICUA group rather than with C. albicans infections.
We observed similar mortality rates for UYS-related and C. albicans fungaemia (P " 0.129 for day 30, P " 0.065 for day 8), and similar survival rates during the first 30 days after diagnosis (log-rank test P " 0.114; Figure S2 ). However, when looking at the species/group level, infections with C. dubliniensis and GEOTRICHUM group isolates had a significantly higher mortality rate at day 30, but not at day 8 for the GEOTRICHUM group; infections with Trichosporon spp., KEFYR and GUILLIERMONDII groups showed no difference in their mortality rates; and infections with C. lusitaniae were associated with a lower mortality rate than those with C. albicans (Table S3, Figure S2 ). In the multivariate analysis, independent risk factors for death at day 30 and day 8 were age, a solid tumour, the lack of antifungal prescription within the Bretagne et al.
first 48 h of diagnosis and, only for death at day 30, the isolate involved when it was C. dubliniensis or from the GEOTRICHUM group (Table S3) . Only univariate analysis was performed for S. cerevisiae (n " 11), and Candida utilis (n " 10) (Table S4 ). Differences in mortality rate at day 30 were observed between S. cerevisiae (no death, P " 0.007) and C. utilis (mortality rate"80%, P " 0.018) versus 40% for C. albicans. No specific analysis was performed for the other species with fewer than 8 isolates.
When looking at the initial antifungal treatment of UYS fungaemia reported by the clinicians, we observed a steady (P , 0.0001) increase of caspofungin over time for the incident fungaemia enrolled in the YEASTS programme, and, as a consequence, a significant increase (P , 0.0001) of pre-exposure to caspofungin (Table S1 ). When comparing UYS with C. albicans as a reference, we observed less fluconazole use and more caspofungin and lipid formulations of amphotericin B (Lip-AmB) compared to treatments used for C. albicans fungaemia ( Table 2) . This lower use of fluconazole was not only observed for Trichosporon spp. and the GEOTRICHUM and INCONPICUA groups but also for the KEFYR group and C. lusitaniae (Table S4) . Lip-AmB treatment was more prescribed for the GEOTRICHUM group and Trichosporon spp. and also for the KEFYR group than for C. albicans infections. Compared with patients with C. albicans infections. c P value is with reference to C. albicans infection, logistic regression final model (variables entered in the initial model are highlighted in bold; initial treatment and death were not introduced in the model).
Uncommon yeast species-related fungaemia JAC Discussion UYS fungaemia occurred in the 27 YEASTS centres at an overall rate of 9.5% over the study period. Not all invasive fungal infections are associated with positive blood cultures, but considering only positive blood culture allows more homogeneous sampling and reporting. Comparison with other databases is difficult because UYS species are usually analysed with non-albicans Candida species and not by themselves. However, their frequency is usually below 10%. 5 No significant increase in the proportion of UYS was observed in the YEASTS programme, whereas that of C. albicans and C. glabrata fungaemia increased in patients hospitalized in ICU between 2004 and 2009. 15 The incidence of C. albicans fungaemia was 0.22/10 000 days of hospitalization in 2009, 15 and thus the calculated incidence of UYS fungaemia was approximately 0.04 episodes/10 000 days of hospitalization.
The main finding was the large variety of species recovered with several differences in terms of epidemiology and risk factors. The UYS encompassed 35 species belonging to very different taxonomic groups, each with its own susceptibility profile to antifungal drugs. The antifungal susceptibility profiles that we determined were in line with expectations for the genus/species identified, and there was no change over time. 25, 26 As expected, caspofungin-LS species were associated with pre-exposure to caspofungin and we confirmed that this drug can also select fluconazole-LS species. 27 However, pre-exposure to caspofungin has not yet translated into an increase in caspofungin-LS UYS over time despite caspofungin being approved as long ago as 2001 in France. The pressure of fluconazole seems less important, except for Candida norvegensis and Candida inconspicua. We cannot deny a role for other azoles but the use of itraconazole was minimal for prophylaxis or as empirical treatment in the Parisian hospitals, voriconazole was restricted to invasive aspergillosis treatment and posaconazole was launched only after 2009. In any case, the antifungal pressure hardly explains the occurrence of UYS species with low fluconazole and caspofungin MIC values.
Given the phylogenetic diversity of the species involved, considering the UYS as a whole was not clinically relevant. Indeed, the multivariate analysis showed a positive association between haematology and pre-exposure to antifungals for UYS but, when splitting UYS into different taxonomic groups, only a few of them remained associated with haematology and/or pre-exposure to caspofungin. Marked differences in frequency, antifungal susceptibility and virulence supported distinct analyses according to species or groups of species.
Among the three groups that remained associated with haematology after multivariate analysis, the KEFYR group has low MICs to antifungal drugs and a mortality rate similar to that of C. albicans. The food origin of C. kefyr along with possible coldchain disturbance in hot periods has been advocated to explain the summer seasonality reported by some authors, 8 which we did not confirm here. The broad antifungal susceptibility of this group can hardly explain the occurrence of these species in the context of haematological malignancy and pre-emptive/empirical/ prophylactic treatments. In contrast, the GEOTRICHUM group was clearly associated with haematology, breakthrough infections and, more importantly, with an excess of mortality. 28 It was even an independent risk factor for death before day 30 (not early death). Of note, none of these S. clavata isolates belonged to the outbreak clone reported in France. 29 Infections due to isolates of the GEOTRICHUM group were as frequent as those due to Trichosporon spp. This contrasts with reviews based on publications, 1 and may be related to misidentifications before advances in molecular identification. 7, 30 The Trichosporon spp. encompassed six different species including Trichosporon asahii as the main species. 7 No significant association with intravascular devices was observed compared to C. albicans, in contrast to a publication suggesting a predisposition of T. asahii to form biofilms. 2 Despite high caspofungin MICs, a characteristic of all basidiomycetes, there was no excess in mortality for the Trichosporon species.
C. lusitaniae (n " 59) was the second most frequently found yeast after the KEFYR group (n " 69) and, like C. kefyr, exhibited low caspofungin and fluconazole MIC values. We did not confirm the association with prior antifungal treatment suggested in several publications. 3, 6, 16 In the multivariate analysis, only surgery was negatively associated with C. lusitaniae fungaemia and the mortality rate was lower than that of C. albicans fungaemia as already reported, 12 possibly due to C. lusitaniae having a lower toxic effect than C. albicans on host cells. 31 In the multivariate analysis, C. lusitaniae was not associated with a decreased risk of death, suggesting the predominant importance of the pre-existing conditions (age, ICU, malignancy).
C. dubliniensis (n " 37) is closely related to C. albicans and was the third most frequent species, although its overall proportion was lower than reported elsewhere (0.9% versus 2%). 16 The MIC profiles of C. dubliniensis and C. albicans are essentially the same. Our data show that C. dubliniensis was associated with HIV infection, as already published, 13 and with SOT, but not with intravenous drug use as previously reported. 16 The main observation was the higher mortality rate than C. albicans, confirmed by the multivariate analysis identifying that species was an independent risk factor for death at day 30 (not early death). This contradicts other results suggesting that C. dubliniensis is less pathogenic than C. albicans. 32 This finding underlines the importance of precise identification to the species level since many of the isolates were sent to us as C. albicans prior to the routine use of MALDI-TOF in mycology laboratories.
The GUILLIERMONDII group was not associated with haematology or cancer patients in contrast to what is inferred from literature reviews. 10 We did not observe grouped cases (in a given centre over a short period of time), in contrast to the findings of other researchers. 10 We found an association with intravenous drug use, consistent with its environmental source. 33 Infection with isolates of the GUILLIERMONDII group was associated with pre-exposure to caspofungin in accordance with their caspofungin MICs being higher than that of C. albicans.
Previous fluconazole treatment of selected yeasts of the INCONSPICUA group that were also associated with acute leukaemia, as are C. glabrata and C. krusei fungaemia, 15, 11 suggested that the biology of these four species might be closer than that of C. albicans. S. cerevisiae fungaemia has often been ascribed to prescription of the live yeast Saccharomyces boulardii, which is indistinguishable from S. cerevisiae, but this information was not recorded in our database. We did not confirm that patients at risk of S. cerevisiae fungaemia included those in ICU and those with central venous catheters. These previous associations could be due to the incidental prescription of S. boulardii in ICU wards reporting S. cerevisiae fungaemia.
1,9,14 The main observation here Bretagne et al.
was the null mortality rate. Moreover, 8 of the 11 patients with S. cerevisiae fungaemia were treated with fluconazole, despite high fluconazole MICs, with no obvious adverse outcome. Thus, reviews based on case reports may over-emphasize observations of poor outcome. 9, 14 Conversely, our prospectively collected data suggest a very low virulence of this yeast compared to C. albicans.
For the other species, it is hard to draw clear conclusions even though the present collection is the largest ever published. C. utilis is reported only as case reports and 10 cases were gathered here. We did not observe any particular behaviour compared with C. albicans, except the higher mortality (80% at day 30, P " 0.018). As with S. cerevisiae, C. utilis is widely used in the food and cosmetic industries, 34 but seems to be much more virulent than C. albicans for humans.
Analysis of treatments and their impact on prognosis is complicated since only the initial treatment was recorded. Indeed, many patients received several lines of different antifungals over time for fungaemia as well as for concomitant mould infections. Similarly, catheter management could not be ascertained despite strong recommendations for catheter removal. [35] [36] [37] We should emphasize here that initial treatments were not based only on known susceptibility of the species identified. While caspofungin was used less frequently to treat Geotrichum and Trichosporon spp. infections, probably based on the known caspofungin resistance of these species, 7,28 more Lip-AmB or caspofungin than fluconazole were prescribed for C. kefyr despite the known wide susceptibility of this species. 25 Other considerations, mainly haematological, were probably taken into account for these patients. Therefore, it is not possible to discuss here how well the antifungal treatments matched the corresponding MIC values. Moreover, we should keep in mind that MIC results were usually not available at the time of species identification. Thus, the first antifungal drug prescribed is only a partial view of the therapeutic management and may not follow recent recommendations for UYS. 35 We note here the recent recommendations for more caspofungin prescription for candidaemia in general, 36, 37 and more Lip-AmB for associated mould infections in haematology wards. It is noteworthy that only the lack of antifungal drug prescription was an independent risk factor for death (Table 4) .
This study has several limitations. The mortality observed for some UYS could be due to numerous other clinical factors not studied here, such as evolution of the underlying disease, organ failure, toxicity and side effects prevailing for some antifungals, all impacting prognosis. However, multivariate analysis on large Final model for early death does not include the species (P " 0.3875).
Uncommon yeast species-related fungaemia JAC panels of prospectively collected fungaemia is a means to minimize bias. The follow-up beyond 30 days could also have provided interesting information on late complications. 4 Another limitation is the grouping of several UYS, which may be questionable to expert taxonomists, but was the only means to increase sample size. Finally, micafungin or anidulafungin are now recommended as surrogate markers of resistance to the candin class owing to inconsistent interlaboratory test results for caspofungin. 38 Since our data collection started in 2002, only caspofungin MICs were available for all the isolates. Additionally, all MIC values were obtained in the same laboratory (the NRCMA), ruling out the problem of interlaboratory variability.
Based on a large database collected prospectively over more than a decade, our analysis provides evidence that, in addition to their known phylogenetic diversity, UYS responsible for fungaemia display specific host characteristics, susceptibility to antifungals and virulence. We therefore strongly underline the major contribution that identification to the species level can make to the optimal management of UYS fungaemia at the hospital level and the need for confirmation by reference laboratories for epidemiological studies.
